Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Sold by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP lessened its holdings in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 11.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,120,027 shares of the company’s stock after selling 150,000 shares during the period. Inozyme Pharma accounts for approximately 1.4% of Blue Owl Capital Holdings LP’s holdings, making the stock its 21st biggest position. Blue Owl Capital Holdings LP owned 1.81% of Inozyme Pharma worth $4,995,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of INZY. Deerfield Management Company L.P. Series C bought a new stake in shares of Inozyme Pharma during the 2nd quarter valued at about $52,000. Meeder Asset Management Inc. bought a new stake in shares of Inozyme Pharma during the 2nd quarter valued at about $68,000. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma during the 2nd quarter valued at about $76,000. Cubist Systematic Strategies LLC bought a new stake in shares of Inozyme Pharma during the 2nd quarter valued at about $84,000. Finally, The Manufacturers Life Insurance Company grew its position in Inozyme Pharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company’s stock worth $96,000 after purchasing an additional 2,690 shares during the last quarter. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Stock Up 0.8 %

INZY stock opened at $5.18 on Friday. Inozyme Pharma, Inc. has a 12-month low of $2.69 and a 12-month high of $7.80. The company has a quick ratio of 9.84, a current ratio of 9.84 and a debt-to-equity ratio of 0.48. The company has a market cap of $320.41 million, a price-to-earnings ratio of -3.78 and a beta of 1.52. The company has a 50 day moving average of $5.26 and a two-hundred day moving average of $5.13.

Inozyme Pharma (NASDAQ:INZY) last posted its earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). On average, equities analysts anticipate that Inozyme Pharma, Inc. will post -1.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INZY has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Inozyme Pharma in a research report on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research report on Tuesday, August 6th. Jefferies Financial Group restated a “buy” rating and issued a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Stifel Nicolaus initiated coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $15.00 target price on shares of Inozyme Pharma in a research report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $16.14.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.